What is Dyax Effective Interest Rate on Debt %?
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Dyax's annualized positive value of Interest Expense for the quarter that ended in Sep. 2015 was $13.70 Mil. Dyax's average total debt for the quarter that ended in Sep. 2015 was $82.11 Mil. Therefore, Dyax's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2015 was 16.69%.
Dyax Effective Interest Rate on Debt % Historical Data
The historical data trend for Dyax's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyax Effective Interest Rate on Debt % Chart
|
Dyax Annual Data
|
|
Trend |
Dec05 |
Dec06 |
Dec07 |
Dec08 |
Dec09 |
Dec10 |
Dec11 |
Dec12 |
Dec13 |
Dec14 |
| Effective Interest Rate on Debt % |
|
Get a 7-Day Free Trial
|
|
|
20.46 |
15.47 |
13.54 |
13.33 |
13.26 |
|
Dyax Quarterly Data
|
|
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Dec13 |
Mar14 |
Jun14 |
Sep14 |
Dec14 |
Mar15 |
Jun15 |
Sep15 |
| Effective Interest Rate on Debt % |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
13.39 |
13.24 |
13.19 |
13.18 |
16.69 |
Competitive Comparison of Dyax's Effective Interest Rate on Debt %
For the Biotechnology subindustry, Dyax's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyax's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyax's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Dyax's Effective Interest Rate on Debt % falls into.
Dyax Effective Interest Rate on Debt % Calculation
Dyax's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2014 is calculated as
| Effective Interest Rate on Debt % |
| = | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2013 ) | + | Total Debt (A: Dec. 2014 )) | / count ) |
| = | -1 * -10.917 | / | ( (82.447 | + | 82.165) | / 2 ) |
| = | -1 * -10.917 | / | 82.306 |
| = | 13.26 % |
where
Dyax's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2015 is calculated as
| Effective Interest Rate on Debt % |
| = | -1 * Interest Expense | / | ( (Total Debt (Q: Jun. 2015 ) | + | Total Debt (Q: Sep. 2015 )) | / count ) |
| = | -1 * -13.704 | / | ( (82.111 | + | 0) | / 1 ) |
| = | -1 * -13.704 | / | 82.111 |
| = | 16.69 % |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Sep. 2015) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Dyax (DYAX) Business Description
Traded in Other Exchanges
N/A
Address
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
| David J Mclachlan |
other: Former director |
ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
| Gustav Christensen |
officer: CEO and President, other: Former director |
DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Todd Bazemore |
officer: EVP & Chief Commercial Officer |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Thomas L Kempner |
other: Former director |
C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004 |
| Abbie Celniker |
other: Former director |
C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142 |
| Marc D Kozin |
other: Former director |
|
| Andrew D. Ashe |
officer: General Counsel & EVP |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Ron Cohen |
other: Former director |
C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
| Mary Ann Gray |
other: Former director |
201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
| George V Migausky |
officer: EVP & Chief Financial Officer |
C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Paolo Pucci |
other: Former director |
C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
| Burt A Adelman |
officer: CMO & EVP, R&D |
DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Ivana Magovcevic-liebisch |
officer: EVP; Chief Operating Officer |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Susan B Bayh |
director |
WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
| Stephen S Galliker |
officer: EVP and CFO |
300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DYAX has been successfully added to your